Neomorph is a clinical-stage biotechnology company pioneering the discovery and development of molecular glue degraders to unlock new therapeutic possibilities across serious diseases. By engineering neomorphic protein surfaces, Neomorph enables precision targeted protein degradation of disease drivers that have historically been considered undruggable.

As a leader in molecular glue technology, Neomorph has created the world’s largest proprietary molecular glue target space, spanning multiple novel degrons across an expansive portfolio of E3 ubiquitin ligases. The company was founded in 2020 and is venture-backed by Deerfield Management Company.